S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:PBYI

Puma Biotechnology Stock Forecast, Price & News

$9.96
-0.59 (-5.59 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.92
Now: $9.96
$11.06
50-Day Range
$10.55
MA: $11.67
$13.63
52-Week Range
$5.50
Now: $9.96
$14.14
Volume447,975 shs
Average Volume419,992 shs
Market Capitalization$396.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.39
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology logo

Headlines

Is PBYI A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Employees269
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$272.30 million
Book Value$0.45 per share

Profitability

Net Income$-75,600,000.00

Miscellaneous

Market Cap$396.03 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

379th out of 1,960 stocks

Pharmaceutical Preparations Industry

190th out of 771 stocks

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$9.96
-0.59 (-5.59 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

Is Puma Biotechnology a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology
or view top-rated stocks.

What stocks does MarketBeat like better than Puma Biotechnology?

Wall Street analysts have given Puma Biotechnology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Puma Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a drop in short interest in January. As of January 15th, there was short interest totaling 4,880,000 shares, a drop of 26.9% from the December 31st total of 6,680,000 shares. Based on an average trading volume of 547,200 shares, the short-interest ratio is presently 8.9 days. Approximately 14.5% of the shares of the company are short sold.
View Puma Biotechnology's Short Interest
.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Puma Biotechnology
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its quarterly earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.07. Puma Biotechnology had a negative net margin of 23.86% and a negative trailing twelve-month return on equity of 451.50%.
View Puma Biotechnology's earnings history
.

How has Puma Biotechnology's stock been impacted by COVID-19?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBYI stock has increased by 7.4% and is now trading at $9.96.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PBYI?

7 equities research analysts have issued 1 year price objectives for Puma Biotechnology's shares. Their forecasts range from $9.00 to $17.00. On average, they expect Puma Biotechnology's share price to reach $13.14 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts' price targets for Puma Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 51, Pay $1.3M)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 52, Pay $665.8k)
  • Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 64, Pay $720.3k)
  • Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management (Age 56, Pay $523.83k)
  • Mr. Mariann Ohanesian, Sr. Director of Investor Relations
  • Charon Spencer Sr., VP of HR
  • Mr. Jeffrey Jerome Ludwig, Chief Commercial Officer (Age 55)

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.53%), Renaissance Technologies LLC (4.18%), Jupiter Asset Management Ltd. (1.83%), Rice Hall James & Associates LLC (1.52%), Morgan Stanley (1.26%) and Northern Trust Corp (0.92%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends for Puma Biotechnology
.

Which institutional investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Panagora Asset Management Inc., JPMorgan Chase & Co., Credit Suisse AG, Russell Investments Group Ltd., Principal Financial Group Inc., Sei Investments Co., and Barclays PLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Maximo F Nougues, Richard Paul Bryce, and Troy Edward Wilson.
View insider buying and selling activity for Puma Biotechnology
or view top insider-selling stocks.

Which institutional investors are buying Puma Biotechnology stock?

PBYI stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Jupiter Asset Management Ltd., BlackRock Inc., Squarepoint Ops LLC, Strs Ohio, Rice Hall James & Associates LLC, and Prospera Financial Services Inc.
View insider buying and selling activity for Puma Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $9.96.

How much money does Puma Biotechnology make?

Puma Biotechnology has a market capitalization of $396.03 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does Puma Biotechnology have?

Puma Biotechnology employs 269 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Where are Puma Biotechnology's headquarters?

Puma Biotechnology is headquartered at 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.